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Abstract
Background: Appropriate antibiotic prescribing is associated with favourable levels of antimicrobial resistance
(AMR) and clinical outcomes. Most intervention studies on antibiotic prescribing originate from settings with high
level of AMR. In a Norwegian hospital setting with low level of AMR, the literature on interventions for promoting
guideline-recommended antibiotic prescribing in hospital is scarce and requested. Preliminary studies have shown
improvement potentials regarding antibiotic prescribing according to guidelines. We aimed to promote appropriate
antibiotic prescribing in patients with community-acquired pneumonia (CAP) and acute exacerbations of chronic
obstructive pulmonary disease (AECOPD) at a respiratory medicine department in a Norwegian University hospital.
Our specific objectives were to increase prescribing of appropriate empirical antibiotics, reduce high-dose
benzylpenicillin and reduce total treatment duration.
Methods: We performed an audit and feedback intervention study, combined with distribution of a recently published
pocket version of the national clinical practice guideline. We included patients discharged with CAP or AECOPD
and prescribed antibiotics during hospital stay, and excluded those presenting with aspiration, nosocomial
infection and co-infections. The pre- and post-intervention period was 9 and 6 months, respectively. Feedback
was provided orally to the department physicians at an internal-educational meeting. To explore the effect of
the intervention on appropriate empirical antibiotics and mean total treatment duration we applied before-after analysis
(Student’s t-test) and interrupted time series (ITS). We used Pearson’s χ2 to compare dose changes.
Results: In the pre-and post-intervention period we included 253 and 155 patients, respectively. Following the
intervention, overall mean prescribing of appropriate empirical antibiotics increased from 61.7 to 83.8 % (P < 0.001),
overall mean total treatment duration decreased from 11.2 to 10.4 days (P = 0.015), and prescribing of high-dose
benzylpenicillin decreased from 48.8 to 38.6 % (P = 0.125). With ITS we found that six months post-intervention, the
effect on appropriate empirical antibiotic prescribing had increased and sustained, while the effect on treatment
duration was at pre-intervention level.
Conclusion: The combination of audit and feedback plus distribution of a pocket version of guideline
recommendations led to a substantial increase in prescribing of appropriate empirical antibiotics, which is important
due to favourable effect on AMR and clinical outcomes.
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Background
Appropriate antibiotic prescribing against Community-
Acquired Pneumonia (CAP) and Acute Exacerbation of
Chronic Obstructive Pulmonary Disease (AECOPD) may
reduce risk of treatment failure, hospital readmission,
mortality and health care costs, increase quality of life,
and delay development of antimicrobial resistance
(AMR) [1, 2]. Appropriate antibiotic prescribing includes
selection of guideline-recommended empirical antibiotic
treatment, dose and total treatment duration [2, 3]. Em-
pirical antibiotic selection in Norway is mainly based on
level of AMR amongst S.pneumoniae, which is the com-
monest bacterial pathogen in CAP and AECOPD [4–6].
Other pathogens include H.influenzae, M.pneumoniae
and respiratory viruses [4–6]. In Norway, <1 % of
S.pneumoniae are resistant to benzylpenicillin [7]. For
H.influenzae, the prevalence of beta-lactamase and
chromosomal resistance is 15 % and 19 %, respectively
[6, 7]. Consequently, recommended empirical prescrib-
ing in Norway for non-severe hospitalized CAP and
AECOPD-patients is benzylpenicillin (low-dose 1.2 g x
4) or amoxicillin/ampicillin. In severe hospitalized pa-
tients, the recommended prescribing is benzylpenicillin
(high-dose 3.0 g x 4) in monotherapy or in combination
with gentamicin, or cefotaxime in monotherapy as sec-
ond choice. A macrolide is added if atypical pathogens
such as M.pneumoniae are suspected [6].
Inappropriate antibiotic prescribing related to empir-
ical antibiotic selection and total treatment duration is
frequently reported for both CAP and AECOPD patients
[8, 9]. Interventions of persuasive or restrictive character
to promote appropriate prescribing are equally effective
after six months, but restrictive interventions have
greater immediate impact [10]. Audit and feedback
(A&F), applied alone or in combination with other inter-
ventions, is a persuasive strategy for improving profes-
sional practice [11]. In A&F you audit clinical practice
within a specific time period and compare results with
standards or targets. Healthcare professionals are then
informed about the results, orally, in writing or both.
The goal is adjustment of clinical practice to approach
standards or reach targets [11]. Most intervention stud-
ies originate from countries with high level of AMR and
a prescribing pattern that differ from Norway. In the
Norwegian setting, with extensive prescribing of benzyl-
penicillin and low level of AMR, the literature on inter-
ventions for promoting appropriate hospital prescribing
is requested [12]. The overall aim of this study was to
promote appropriate antibiotic prescribing in CAP and
AECOPD patients at a respiratory medicine department
in a Norwegian hospital. Specific objectives were to in-
crease prescribing of appropriate empirical antibiotics,
reduce prescribing of high-dose benzylpenicillin and
shorten total treatment duration.
Method
We performed a three-phase A&F intervention study at
an 18-bed respiratory medicine department at the Uni-
versity Hospital of North Norway (UNN) Tromsø. UNN
is a 500-bed hospital, and serves as local hospital for
about 190 000 inhabitants. We included all patients
discharged with CAP or AECOPD that were prescribed
antibiotics during their hospitalization. Patients with co-
infections, nosocomial pneumonia and aspiration pneu-
monia were excluded. See Fig. 1.
Pre-intervention phase (January 1 – September 30, 2014)
We used the electronic hospital administrative system to
identify eligible patients discharged during the nine-
month pre-intervention audit. We assessed antibiotic
prescribing practice by retrospectively reviewing medica-
tion charts and electronic patient records, denoting pre-
defined data in data collection forms. For each patient
we evaluated whether antibiotic prescribing was in ac-
cordance with national clinical practice guideline (CPG)
recommendations, see Table 1 [6]. In the pre-
intervention audit we focused on empirical antibiotic se-
lection, dose and treatment duration. Specifically, we tar-
geted prescribing of empirical antibiotics categorizing
the prescribing as either appropriate (i.e. benzylpenicillin
in monotherapy, in combination with gentamicin, or
amoxicillin/ampicillin in monotherapy) or inappropriate
(i.e. all other antibiotics). The proportion of appropriate
empirical antibiotics maintained during first three days
and during entire hospital stay were measured, but not
targeted. We also targeted dose of benzylpenicillin (i.e.
high-dose 3 g x 4 and low-dose 1.2 g x 4), and total
treatment duration. The latter was calculated as length
of inpatient prescribing plus length of prescription at
discharge. We extracted data on 30-day mortality and
30-day unplanned readmission of any cause from the
electronic patient journal.
The feedback (September 2014)
The head of the respiratory medicine department
summoned all the department physicians to attend
the feedback session where we presented the project,
the essential CPG recommendations and the results
of the pre-intervention audit. In addition, we distrib-
uted the recently published pocket version of the
national CPG. The physicians were encouraged to
discuss audit results, especially with focus on the
identified discrepancies between documented per-
formance and the CPG recommendations. While the
principal investigator (JUH) led the feedback session,
an infection disease (ID)-specialist (VS) took active
part in the discussion and commented on CPG rec-
ommendations and audit results.
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Post-intervention phase (October 1, 2014 – March 31, 2015)
We conducted the post-intervention audit in the same
manner as the pre-intervention audit, but the audit was
restricted to six months due to time constraints.
The Regional Committee for Medical and Health Re-
search Ethics assessed the study, and concluded that the
procedure was a qualitative improvement initiative and
outside their remit to evaluate. The hospital’s personal
data protection officer approved the study. The need for
informed consent was wavered because patient data was
retrospectively and anonymously extracted from patient
records and consequently did not put patients at any
risk, and because the physicians taking part in the study
did this as part of their daily working routine. All data
are aggregated data, reported anonymously, and patient
confidentially is maintained.
Statistics
We compared patient characteristics in the pre- and
post intervention period using Pearson’s χ2-test for cat-
egorical data and Student’s t-test for continuous data.
The effect of the intervention on overall changes in
prescribing of appropriate empirical antibiotics and
total treatment duration was analysed using before-
and-after analysis (Student’s t-test) and interrupted
time series (ITS). For the latter, we evaluate both a
level effect and a trend effect. Consequently, we esti-
mate both immediate, delayed and sustained effect
while taking into account the time trend [13, 14]. The
regression model is given by:
Ŷ t ¼ β0 þ β1 xtimet þ β2xintervention
þ β3xtime after interventiont þet;
Ŷt is the outcome, β0 is the intercept, β1 is the slope
pre-intervention, β2 is the change in level one and six
months post-intervention, β3 is the change in slope
post-intervention compared to pre-intervention (change
in trend), and et is the error estimate [13, 14]. Change in
level is the difference between the last point pre-
intervention and the point of interest post-intervention (e.g.
first point), and the trend change can reverse or enhance a
level change [15]. The analyses were controlled for autocor-
relation and seasonality by applying Durbin-Watson statis-
tics and autocorrelation function plot. For the ITS analysis,
data was processed, analysed and reported in accordance to
relevant guidelines [14, 16].
For comparison of dose differences pre- and post-
intervention, we used the Pearson’s χ2 test. In all tests, a
P-value of < 0.05 was considered statistically significant.
We conducted the statistical analysis using Microsoft®
Office Excel 2013 and SPSS® 22.0 for Windows.
Results
Patient characteristics
In the pre- and post-intervention phase we included 253
and 155 patients, respectively. A significant decrease
from pre- to post-intervention was observed concerning
proportion of patients with AECOPD and penicillin al-
lergy. Following the intervention, we observed no nega-
tive effect on 30-day mortality, 30-day readmission and
length of stay in hospital (Table 2). For detailed
Fig. 1 Overview of the three-phase audit and feedback intervention study
Table 1 An abbreviated overview of the Norwegian clinical practice-guideline recommendations
Infection Drug Dose Duration
AECOPD Benzylpenicillin (intravenous)Ampicillin
(intravenous)Amoxicillin (oral)
1.2 g x 41.0 g x 4500 mg x 3 5 days





(intravenous)+ alternatively addition of
erythromycin (intravenous or oral)
3 g x 45 mg/kg x 11–2 g x 3500 mg x 4 7–10 days
Valid for hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and community-acquired pneumonia (CAP)
CRB-65 Confusion, respiration, blood pressure and age > 65y. aIn analysis categorized as inappropriate, see discussion
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information on differences in study outcome measures
for appropriate and inappropriate empirical antibiotic pre-
scribing, see Additional file 1. For detailed information on
microbiological diagnostics and findings, see Additional
files 2, 3 and 4.
Prescribing of appropriate empirical antibiotics
During the feedback we agreed with department physi-
cians to target increased prescribing of appropriate em-
pirical antibiotics. Following the intervention, the overall
mean prescribing of appropriate empirical antibiotics
Table 2 Patient characteristics of patients included pre- and post-intervention
Pre-intervention Post-intervention P-value
n (%) n (%)
Study participants 253 155
Female 126 (49.8) 75 (48.4) NS
Age, years NS
Mean (range) 71.4 (78) 72.1 (75)
Median 73.0 73.0
Infection
AECOPD 104 (41.4) 45 (29.0) 0.014
Community-acquired pneumonia 149 (58.9) 110 (71.0)
Nursing home residents 25 (9.9) 9 (5.8) NS
Penicillin allergy 32 (12.6) 9 (5.8) 0.03
Risk factors for non-common bacteria or resistant bacteria
Malignity or immunocompromised 36 (14.2) 24 (15.5) NS
Preceding hospitalization last 30d 57 (22.5) 24 (15.5) NS
Microbiological diagnostics
Blood culture 172 (68.0) 125 (80.6) 0.005
Nasopharynx and/or expectorate 205 (81.0) 141 (91.0) 0.007
Pneumococcal urinary antigen test 149 (58.9) 92 (59.4) NS
Othera 157 (62.1) 104 (67.1) NS
None 16 (6.3) 5 (3.2) NS
Aetiology
S.pneumoniae 30 (11.9) 16 (10.3) NS
H.influenzae 12 (4.7) 13 (8.4) NS
Other bacteria 15 (5.9) 11 (7.1) NS
Influenza virus A or B 24 (9.6) 18 (11.6) NS
Other respiratory viruses 34 (13.4) 30 (19.4) NS
None identified 159 (62.8) 89 (57.4) NS
CRB-65 score NS
0 25 (16.8) 16 (14.5)
1 57 (38.3) 42 (38.2)
2 48 (32.2) 32 (29.1)
3 7 (4.7) 11 (10.0)
4 2 (1.3) 1 (0.9)
Missing data 10 (6.7) 8 (7.3)
Clinical outcomes
Length of stay, median (range) 5.3 (34) 5.9 (33) NS
30 day mortality 18 (7.1) 14 (9.0) NS
30 day readmission 55 (22.8) 24 (16.7) NS
AECOPD Acute exacerbation of chronic obstructive pulmonary disease, CRB-65 Confusion, respiration, blood pressure and age ≥ 65y, aHigh prevalence due to
urinary samples are included. For more detailed information on microbiological diagnostics, see Additional files 2, 3 and 4
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increased from 61.7 to 83.8 %, P < 0.001. The most
prominent changes were appropriate antibiotics re-
placing doxycycline in AECOPD-patients and cephalos-
porines in CAP-patients (Table 3).
Using the monthly proportion of appropriate empirical
antibiotics prescribed, we analysed trend and level change
with ITS. Pre-intervention, the prescribing slope of appro-
priate empirical antibiotics non-significantly decreased 1.3
% per month. The immediate effect of the intervention was
non-significant (estimated level change; +14.1 %, P >0.05).
However, post-intervention, the trend of appropriate empir-
ical antibiotics significantly increased (trend change; + 4.1
% per month, P = 0.02), and six months post-intervention
the effect of the intervention was significant (estimated
level change; +45.4 %, P = 0.002). See Fig. 2 and Table 4.
In antibiotics categorized as appropriate, 90.9 % and
82.9 % of the prescribing in the pre-intervention audit
was maintained during first three days and during entire
hospital stay, respectively. For both variables the preva-
lence of change was even lower post-intervention.
Total treatment duration
During the feedback we agreed with the physicians to
target a reduction in total treatment duration. Following
the intervention, overall mean total treatment duration
decreased from 11.2 to 10.4 days, P = 0.015. Based on
the monthly mean total treatment duration, the ITS
showed a non-significant decreasing trend in mean total
treatment duration in the pre-intervention phase (−0.07
days per month, P > 0.05). Post-intervention, there was
an immediate and significant reduction in mean total
treatment duration (estimated level change; −1.4 days,
P = 0.04). However, post-intervention the trend of
mean total treatment duration significantly increased
(trend change; + 0.27 days per month, P = 0.03), and
six months post-intervention the effect of the intervention
was no longer significant and back to pre-intervention
level (estimated level change; +0.57 days, P > 0.05). See
Fig. 3 and Table 4.
Dose of benzylpenicillin
The physicians agreed on targeting a change in pre-
scribing from high to low dose of benzylpenicillin.
Following the intervention, the proportion of patients
prescribed high-dose benzylpenicillin decreased from
48.8 to 38.6 %, P = 0.125.
Discussion
In a Norwegian hospital setting, an A&F intervention com-
bined with distribution of a pocket version of the national
CPG led to a substantial and sustained increased prescrib-
ing of appropriate empirical antibiotics. A significant imme-
diate reduction on total treatment duration was transitory
and vanished six months post-intervention. With the inter-
vention, we achieved a 10 percentage-point targeted reduc-
tion in prescribing of high-dose benzylpenicillin.
Empirical antibiotic prescribing
To halt development and spread of AMR, appropriate
prescribing of antibiotics in addition to effective infec-
tion control programmes, is important [7]. Increasing
levels of extended-spectrum beta-lactamase producing
gram negative bacteria has been observed in Norwegian
hospitals the recent years, probably associated with im-
port of resistant strains, either in patients or food, and
possibly also increasing domestic use of cephalosporines
and fluroquinolones [7]. Consequently, testing different
intervention approaches to reduce use of known drivers for
resistance is important. Particularly, use of cephalosporines
and fluroquinoles can result in co-selection of resistance to
aminoglycosides, and threaten the Norwegian strategy with
extensive use of benzylpenicillin and gentamicin [17].
Cefotaxime is a part of the Norwegian CPG recommen-
dations for severely ill CAP-patients and it can there-
fore be discussed whether it was correct categorising
cephalosporines as inappropriate and tailor a reduction
in use. In theory, an intervention to reduce cephalos-
porines and other inappropriate antibiotics could have
resulted in undertreatment. During the feedback ses-
sion, the ID-specialist highlighted the importance of
Table 3 Comparison of empirical antibiotic prescribing pre- and post-intervention, expressed as percentage-point difference
Antibiotic agent Pre-intervention (%) Post-intervention (%) Percentage-point difference
Benzylpenicillina 41.1 53.5 +12.4
Benzylpenicillin + gentamicina 8.3 16.1 +7.8
Ampicillin and amoxicillina 12.3 14.2 +1.9
Cephalosporinesb 16.2 9.7 −6.5
Tetracyclinesb 14.6 3.2 −11.0
Macrolides 2.8 - −2.8
Others 4.7 3.2 −1.9
Proportion of patients prescribed the specific antibiotics is calculated based on number of study participants pre- and post-intervention (n = 253 and 155, respectively)
aCategorized as appropriate, and targeted for increase, bFor cephalosporines and doxycyclines percentage difference was −3.8 % and −21.6 % in patients with
acute exacerbation of chronic obstructive pulmonary disease and −11.2 % and −2.0 % in patients with community-acquired pneumonia, respectively
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preferring benzylpenicillin plus gentamicin before cefo-
taxime, but also emphasised that cefotaxime is an alter-
native in patients with severe infection and specific
complexities. Indicated by CRB-65 score, few patients
had a severe infection, and this suggest that cefotaxime
might only be necessary in a minority of patients.
Altogether, we substantially reduced prescribing of
broad-spectrum antibiotics known to promote AMR,
and we succeeded in reducing prescribing of these anti-
biotics with no obvious negative effect on measured
clinical outcomes. Consequently, our results indicate
that an A&F intervention can have positive effect on
empirical antibiotic prescribing and may be expanded
to other settings with low level of AMR.
The high degree of maintained empirical prescribing
suggests a low level of treatment failure. In other studies,
change of empirical prescribing has been reported in 6-
31 % of patients [18–20].
The significant higher proportion of patients with peni-
cillin allergy in the pre-intervention phase may theoretic-
ally have resulted in a higher prevalence of inappropriate
antibiotics prescribing in the pre-intervention phase (i.e.
cephalosporins for non-immediate allergy), which again
may have biased our positive results post-intervention. To
test this, we excluded all patients with penicillin allergy in
both phases, which yielded no significant change of the re-
ported mean, trend- or level effect. It is worth noticing
that the overall prevalence of penicillin allergy in our
study was 12.6 and 5.8 % pre-and post-intervention, which
is far higher than the 1 % estimated prevalence of penicil-
lin allergy [21]. In future, patients erroneously labelled
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Fig. 2 Trend and level change in monthly prescribing of appropriate empirical antibiotics, pre- and post-intervention. Appropriate antibiotics
comprise benzylpenicillin in monotherapy, benzylpenicillin in combination with gentamicin, or amoxicillin/ampicillin. Pre-intervention audit started
January 2014 (point no.1), the intervention was performed late September 2014 (point no. 9) and the post-intervention audit ended March 2015
(point no. 15)
Table 4 Monthly prescribing of appropriate empirical antibiotics and total treatment duration, estimated with interrupted times
series
Appropriate empirical antibioticsa Total treatment duration
Percent P-value SE Days P-value SE
Intercept β0 68.3 5.3 11.5 0.4
Trend before intervention β1 −1.3 ns 0.9 −0.07 ns 0.1
Effect one month after intervention β2 14.1 ns 8.5 −1.4 0.04 0.9
Effect six month after intervention β2 45.4 0.002 11.0 0.57 ns 0.8
Trend change after intervention β3 4.1 0.02 2.9 0.27 0.03 0.14
Trends pre- and post intervention, and effect of the intervention on prescribing one and six months after the intervention (level change) are reported
aComprise benzylpenicillin in monotherapy, benzylpenicillin in combination with gentamicin, or amoxicillin/ampicillin, ns; data is considered non-significant when
P > 0.05, SE Standard error
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patients from more appropriate narrow-spectrum antibi-
otics [21].
The lower proportion of AECOPD in the post-
intervention phase compared to the pre-intervention
phase did not influence our results as empirical prescrib-
ing of both conditions is categorized as appropriate.
Total treatment duration
Short-term antibiotic treatment has in randomized con-
trolled trials (RCTs) shown the same efficacy as long-term
treatment with regards to clinical-, bacteriological- and
radiological success [22]. Reducing total treatment duration
is important, both to increase patient compliance, reduce
risk of adverse effects and to reduce AMR development
[23]. For beta-lactams, 3–5 days treatment has been found
to be safe [22, 24]. In a European multicentre study includ-
ing 14 centres from three countries, mean duration was 8.9
and 11 days for AECOPD and CAP patients, respectively
[9]. Appropriate treatment duration of antibiotics seems to
be neglected and interventions are requested [23, 25].
Multifaceted prospective interventions by antimicro-
bial stewardship teams have been shown effective in
order to reduce length of antibiotic treatment. Avdic et
al. showed that a team comprising an ID-specialist and a
clinical pharmacist recommended reduction of duration
of antibiotic treatment in 59 % of patients by applying
an algorithm suggesting the appropriate duration. The
mean treatment duration was reduced from 10 to 7 days
[26]. Lesprit et al. showed a reduction in mean antibiotic
treatment duration from 10 to 7 days in a multicentre
RCT in surgical and medical departments, where an ID-
specialist performed systematic reviews of antibiotic pre-
scribing at day 1 and day 3–4 in the intervention group.
No negative effects on clinical outcomes were observed
[27]. In a study by Murray et al., they recommended
antibiotic duration based on a severity score, automatic
stop dates at time of initiating empirical prescribing and
pharmacist feedback to prescribers. Overall, the mean
duration of treatment was reduced from 8.3 to 6.8 days,
with a subsequent reduction of gastrointestinal adverse
effects [28]. A retrospective A&F probably requires fewer
recourses compared to prospective A&Fs, and we there-
fore found it important to test this approach. In our
study, we achieved a smaller reduction in total antibiotic
duration compared with studies based on more compre-
hensive intervention strategies. In future, prospective in-
terventions involving a multidisciplinary approach
should be tested in a Norwegian setting.
Dose of benzylpenicillin
In Norway, there have been concerns about an unjusti-
fied increase in prescribing of high-dose benzylpenicillin
over the recent years [29]. High doses are associated
with increased overall consumption of antibiotics, which
may increase risk of adverse effects and AMR develop-
ment [30–33]. Benzylpenicillin possesses time dependent
killing, and time above the minimum inhibitory concen-
tration (T > MIC) should cover about 50 % of the dosing
interval. Peak efficacy is reached at about 5 times above
MIC [34]. Based on a national high proportion of sus-
ceptible S.pneumoniae (MIC ≤ 0.06 mg/L), most patient
will benefit 1.2 g x 4 (i.e. low dose) [7]. For H.influenzae
Fig. 3 Trend and level change in monthly mean total treatment duration, pre- and post-intervention. Total treatment duration was defined as in-hospital
prescribing plus length of prescription at discharge. Pre-intervention audit started January 2014 (point no. 1), the intervention was performed late Septem-
ber 2014 (point no. 9) and the post-intervention audit ended March 2015 (point no. 15)
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a clinical breakpoint for benzylpenicillin has not been
defined. Time-kill experiments suggested that 3.0 g x 4
(i.e. high dose) can be recommended in H.influenzae
without resistance mechanisms [35]. However, as
H.influenzae rarely results in an invasive infection and is
expected in a minor proportion of patients, the Norwe-
gian CPG have chosen to recommend low-dose benzyl-
penicillin as empirical treatment in non-severe patients
[6]. It is relevant to notice that in case of identified
H.influenzae, a change to high-dose benzylpenicillin
(when susceptible) or to an alternative antibiotic may be
warranted. In severely ill CAP-patients, 3.0 g x 4 is
recommended due to possible altered volume of distri-
bution and protein binding. In our study population,
only 6 and 11 % (pre- and post-intervention) of the
CAP-patients had a severe infection according to CRB-
65. Accordingly, we suspect there is a potential for
improvement beyond 10-percentage point decline in
high-dose benzylpenicillin achieved in this study. How-
ever, this must be further explored.
Behaviour change
At UNN Tromsø, the local infection-, microbiology- and
infection control team have focused upon the import-
ance of appropriate empirical antibiotic prescribing over
several years. This continuous focus may have lowered
the odds of our A&F intervention to increase appropri-
ate empirical antibiotic prescribing. Opposite, there has
been little focus on treatment duration and dose, where
we observed a lower effect of our intervention. Avdic et
al. assessed prescribers’ knowledge and practice related
to antibiotic prescribing of hospitalized CAP-patients.
They observed that most prescribers were uncomfort-
able with short treatment duration, and suspect that pre-
scribers are not up to date on studies supporting short-
time treatment [26]. This is supported in our study by
comments received during feedback session. Physicians
stated that possible explanations on the discrepancies
between audit results and CPG recommendations in-
cluded that they were not up to date on all CPG recom-
mendations and that prescribing often were based on
traditions (i.e. unaware that doxycycline is not recom-
mended for AECOPD and unaware of recommended
treatment duration). Qualitative studies on behaviour
are important in order to identify barriers and tailor
interventions.
Strengths, limitations and lessons learned
ITS design is the “the strongest quasi-experimental
design to evaluate longitudinal effects of time-delimited
interventions” [10]. The advantage with ITS, compared
to using before-after studies only, is that the trend
pre-intervention is accounted for, sustainment of the ef-
fect is explored and graphical presentation facilitate
interpretation of results [36]. Applying a before-after
analysis would have deprived us the opportunity to re-
veal the non-sustainable effect on treatment duration. In
a Cochrane review, it is recommended to include 12
data points both pre-and post-intervention in order to
adequately evaluate seasonality, and to assess the imme-
diate effect and sustainability of the intervention [10].
Moreover, increasing number of observations per data
point reduces variance and provides more stable esti-
mates. Pre-intervention, the trend is non-significantly
decreasing for both empirical antibiotic prescribing and
total treatment duration, which we cannot rule out is
due to variance (fewer patients admitted during summer
months), seasonality or that prescribing is affected by
other factors such as deputies at work during summer
months. Altogether, there exist some limitation on in-
ternal validity in our study. However, the ITS seemed
sensitive to detect change in level and trend. Potential
bias in form of competing interventions cannot be ruled
out without a control to establish our hypothesis. Data
collection was not affected by the intervention and out-
come variables were objectively assessed.
Another strength in our study is that the physicians at
the study department were not informed about the pre-
intervention audit before we presented the audit results.
Consequently, Hawthorne effects can be ruled out. With
regard to the influence on prescribing results, we retro-
spectively acknowledge that our results could have been
even better if we had defined explicit targets together
with the department physicians (e.g. “the target is to
shortening the mean total treatment length to 7 days”).
In addition, providing the feedback both in oral and
written format more frequently, as recommended in a
recent Cochrane review, could have been beneficial [11].
Electronic prescribing and medication charts are not
implemented in the majority of Norwegian hospitals.
Consequently, electronic audit and surveillance is cur-
rently impossible and limits the possibility for feeding
back results as the study progresses. As a consequence
of only providing the feedback once and only orally, we
could not reach all physicians by our intervention.
Despite this, we believe that for instance junior physi-
cians in the emergency department (ED) anyway has
been exposed to advices based on our intervention, as
they frequently turn to the physicians at the respiratory
medicine department when handling CAP and AECOPD
patients. These ED-physicians were not invited to the
feedback session. In addition, junior staff at the clinical
departments rotates every 4–6 months. Consequently,
some that are active during the pre- and post-
intervention phase may not have been present at the
feedback session. However, we emphasize the recom-
mendation from literature that interventions are recom-
mended to target senior physicians, and not junior
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physicians, as the seniors act as supervisors for the less-
experienced physicians [37, 38]. Moreover, lack of adher-
ence to CPGs is more pronounced among seniors com-
pared to juniors [37].
It is relevant to notice that in this study an ID-
specialist had a central role in the intervention team. In
Scandinavian countries the ID-specialist is perceived as
important for antibiotic prescribing [37]. This is in
contrast to countries/settings with a more hierarchical
work system, where it has been found that clinical
leaders and senior physicians overrule the ID-specialists’
advice on antibiotic prescribing [38]. Altogether, it is a
limitation that we only provided the feedback once, but a
possible negative effect of this is probably reduced by high
attendance of senior physicians at the feedback (four out
of five attended) and the active participation of the ID-
specialist.
We emphasise that CPG recommendations does not
address all patient scenarios, and complete adherence to
CPG is probably not desirable. In this study, examples of
justified non-adherence are use of cefotaxime in patients
with severe infection and specific complexities, empirical
antibiotic prescribing in patients with penicillin allergy,
microbiological findings and delayed clinical response.
We have not collected data on this, but it should be con-
sidered for future studies.
Our study has other limitations. First, our study has
limited external validity. Optimally the intervention
should have been performed in multiple hospitals. Sec-
ond, economic and microbiological measures where not
assessed in this study, and should if possible, be included
in future studies. Third, proportion of intensive care
units admissions pre- and post-intervention is also an al-
ternative outcome measure that should be collected to
describe severity of disease in the patient population.
Fourth, CRB-65, which is a well-validated severity-
scoring tool, was not documented in patient records and
we therefore calculated the severity based on informa-
tion at admission. Fifth, we are unable to distinguish the
effect of our A&F intervention from the effect of the
pocket version of the national CPG that was distributed
to all departments at the hospital during same month as
our intervention. Preceding the distribution of this
pocket version, the national CPG was published online
2013 [6]. One the other hand, as literature indicate that
distribution of educational material alone is ineffective,
we do not believe that the effect of this pocket version
may have been substantial in itself [39].
Conclusion
A&F is an essential part of antibiotic stewardship pro-
grams, and testing this design in a setting with low AMR
is important. We have demonstrated improved and sus-
tained prescribing of appropriate empirical antibiotics by
combining an A&F intervention with distribution of a
pocket version of CPG recommendations. The interven-
tion did not have any obvious negative effects on clinical
outcomes. The intervention led to reduced prescribing of
inappropriate antibiotics, such as third generation cepha-
losporins and doxycycline. Our results indicate that A&F
may be suitable for reducing prescribing of broad-
spectrum antibiotics, and the design can potentially be ex-
panded to other low AMR-settings. Following the inter-
vention, we observed a significant immediate reduction in
total treatment duration, however this effect was not sus-
tained after six months. The 10-percentage point reduc-
tion in prescribing of high dose benzylpenicillin was not
significant, but we suspect there is a potential for im-
provement beyond 10-percentage point. In order to
sustain appropriate total treatment duration, defining
explicit targets, and providing the feedback both in oral
and written format more frequently should be tested in
future A&F-studies. In addition, more comprehensive
interventions should be tested. Prospective interven-
tions with antibiotic stewardship teams comprising an
ID-specialist and a clinical pharmacist have shown to
be successful in these aspects.
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